Effects of Netarsudil and Timolol on Retinal Blood Vessel Density and Visual Acuity

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2021

Primary Completion Date

October 31, 2022

Study Completion Date

January 31, 2023

Conditions
OAG - Open-Angle GlaucomaOHT - Ocular Hypertension
Interventions
OTHER

Netarsudil 0.02% QD

This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.

OTHER

Timolol maleate 0.5% BID

This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Aerie Pharmaceuticals

INDUSTRY

lead

University of California, San Diego

OTHER

NCT04064918 - Effects of Netarsudil and Timolol on Retinal Blood Vessel Density and Visual Acuity | Biotech Hunter | Biotech Hunter